These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 29131263)
1. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer. Xi QP; Pu DH; Lu WN Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263 [TBL] [Abstract][Full Text] [Related]
2. CA125 and HE4: Measurement Tools for Ovarian Cancer. Zhao T; Hu W Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726 [TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer. Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570 [TBL] [Abstract][Full Text] [Related]
5. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939 [TBL] [Abstract][Full Text] [Related]
6. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831 [TBL] [Abstract][Full Text] [Related]
7. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095 [TBL] [Abstract][Full Text] [Related]
8. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964 [TBL] [Abstract][Full Text] [Related]
9. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334 [TBL] [Abstract][Full Text] [Related]
10. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125. Li W; Wang D Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526 [TBL] [Abstract][Full Text] [Related]
11. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer. Shen Y; Li L Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144 [TBL] [Abstract][Full Text] [Related]
12. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214 [TBL] [Abstract][Full Text] [Related]
13. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence. Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083 [TBL] [Abstract][Full Text] [Related]
14. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Kristjansdottir B; Levan K; Partheen K; Sundfeldt K Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789 [TBL] [Abstract][Full Text] [Related]
16. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis. Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer. Fan HY; Duan DM; Liu YF Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099 [TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer. Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065 [TBL] [Abstract][Full Text] [Related]
19. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Azzam AZ; Hashad DI; Kamel NA Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]